Lineage Cell Therapeutics, Inc. Net Cash Provided by (Used in) Investing Activities, Continuing Operations
Lineage Cell Therapeutics, Inc. (LCTX) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of -$9.15 million for the 3-month period ending 2017-03-31, per its 10-Q filed 2017-05-10.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2017-05-10
- Lineage Cell Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-03-31 was -$9.15M.
- Lineage Cell Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-12-31 was -$409.00K.
- Lineage Cell Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-09-30 was -$464.00K.
- Lineage Cell Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-06-30 was -$8.35M.
- Lineage Cell Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was -$10.89M.
- Lineage Cell Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$7.44M.
- Lineage Cell Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was -$1.01M.
- Lineage Cell Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2013 was -$3.67M.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month as first filed | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month as first filed | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month as first filed | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2017-03-31 | -$9.15M 10-Q · filed 2017-05-10 | -$9.56M derived: sum of 2 quarters · filed 2017-05-10 | -$10.03M derived: sum of 3 quarters · filed 2017-05-10 | -$18.38M derived: sum of 4 quarters · filed 2017-05-10 | ||||
| 2016-12-31 | -$409.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | -$873.00K derived: sum of 2 quarters · filed 2017-03-16 | -$9.22M derived: sum of 3 quarters · filed 2017-03-16 | -$10.89M 10-K · filed 2017-03-16 | ||||
| 2016-09-30 | -$464.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | -$8.81M derived: sum of 2 quarters · filed 2016-11-04 | -$10.48M 10-Q · filed 2016-11-04 | -$13.07M derived: sum of 4 quarters · filed 2017-05-10 | ||||
| 2016-06-30 | -$8.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | -$10.02M 10-Q · filed 2016-08-09 | -$12.60M derived: sum of 3 quarters · filed 2017-05-10 | -$14.63M derived: sum of 4 quarters · filed 2017-05-10 | ||||
| 2016-03-31 | -$1.67M 10-Q · filed 2017-05-10 | -$4.25M derived: sum of 2 quarters · filed 2017-05-10 | -$6.28M derived: sum of 3 quarters · filed 2017-05-10 | -$8.73M derived: sum of 4 quarters · filed 2017-05-10 | ||||
| 2015-12-31 | -$2.59M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | -$4.62M derived: sum of 2 quarters · filed 2017-03-16 | -$7.07M derived: sum of 3 quarters · filed 2017-03-16 | -$7.44M 10-K · filed 2017-03-16 | ||||
| 2015-09-30 | -$2.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | -$4.48M derived: sum of 2 quarters · filed 2016-11-04 | -$4.85M 10-Q · filed 2016-11-04 | -$5.06M derived: sum of 4 quarters · filed 2017-03-16 | ||||
| 2015-06-30 | -$2.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | -$2.83M 10-Q · filed 2016-08-09 | -$3.04M derived: sum of 3 quarters · filed 2017-03-16 | -$3.13M derived: sum of 4 quarters · filed 2017-03-16 | ||||
| 2015-03-31 | -$373.00K 10-Q · filed 2016-05-10 | -$373.39K 10-Q · filed 2015-05-08 | -$582.00K derived: sum of 2 quarters · filed 2017-03-16 | -$674.00K derived: sum of 3 quarters · filed 2017-03-16 | -$853.38K derived: sum of 4 quarters · filed 2017-03-16 | |||
| 2014-12-31 | -$209.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | -$301.00K derived: sum of 2 quarters · filed 2017-03-16 | -$480.38K derived: sum of 3 quarters · filed 2017-03-16 | -$1.01M 10-K · filed 2017-03-16 | -$1.01M 10-K · filed 2015-03-11 | |||
| 2014-09-30 | -$92.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | -$271.38K derived: sum of 2 quarters · filed 2015-11-09 | -$799.00K 10-Q · filed 2015-11-09 | -$799.36K 10-Q · filed 2014-11-07 | -$2.46M derived: sum of 4 quarters · filed 2016-03-15 | |||
| 2014-06-30 | -$179.38K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | -$707.00K 10-Q · filed 2015-08-10 | -$706.89K 10-Q · filed 2014-08-11 | -$2.36M derived: sum of 3 quarters · filed 2016-03-15 | -$3.58M derived: sum of 4 quarters · filed 2016-03-15 | |||
| 2014-03-31 | -$527.62K 10-Q · filed 2015-05-08 | -$2.19M derived: sum of 2 quarters · filed 2016-03-15 | -$3.40M derived: sum of 3 quarters · filed 2016-03-15 | |||||
| 2013-12-31 | -$1.66M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | -$2.88M derived: sum of 2 quarters · filed 2016-03-15 | -$3.67M 10-K · filed 2016-03-15 | -$3.67M 10-K · filed 2015-03-11 | ||||
| 2013-09-30 | -$1.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07 | -$2.01M 10-Q · filed 2014-11-07 | ||||||
| 2013-06-30 | -$789.55K 10-Q · filed 2014-08-11 | |||||||
| 2012-12-31 | -$104.69K 10-K · filed 2015-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |